Homology modelling of CYP2A6 based on the CYP2C5 crystallographic template: Enzyme-substrate interactions and QSARs for binding affinity and inhibition

Toxicology in Vitro

Volumn 17, Issue 2, 2003, Pages 179-190

  Lewis, D F V ^a   Lake, B G ^b   Dickins, M ^c   Goldfarb, P S ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b BIBRA INTERNATIONAL   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

CYP2A6; Cytochromes P450; Homology modelling; QSARs

Indexed keywords

3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; 4 NITROANISOLE; COTININE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2C5; DICHLOBENIL; FADROZOLE; HALOTHANE; LOSIGAMONE; METHOXYFLURANE; NICOTINE; PARACETAMOL; QUINOLINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTALLOGRAPHY; ENVIRONMENT; ENZYME INHIBITION; HUMAN; METABOLITE; MUTAGENESIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SEQUENCE HOMOLOGY;

EID: 0037376223     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-2333(02)00132-7     Document Type: Article

References (51)

1. Anzenbacher P., Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cellular and Molecular Sciences. 58:2001;737-747.
2. Bourian M., Gullsten H., Legrum W. Genetic polymorphism of CYP2A6 in the german population. Toxicology. 144:2000;129-137.
3. Bourrié M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics. 277:1996;321-332.
4. Chang T.K.H., Waxman D.J. The CYP2A subfamily. Ioannides C. Cytochromes P450 - Metabolic and Toxicological Aspects. 1996;99-134 CRC Press, Boca Raton, FL.
5. Chen W., Koenigs L.L., Thompson S.J., Peter R.M., Rettie A.E., Trager W.F., Nelson S.D. Oxidation of acetamidophen to its toxic quinone imine and nontoxic catechol by baculovirus-expressed and purified human cytochromes P4502E1 and 2A6. Chemical Research in Toxicology. 11:1998;295-301.
6. Ding X., Peng H.-M., Coon M.J. Heterologous expression and structure-function analysis of CYP2A10 and CYP2A11, which differ in only eight amino acids but have strikingly different activities toward testosterone and coumarin. Lechner M.C. Cytochrome P450. 1994;885-888 Libbey, Paris.
7. Evans W.E., Relling M.V. Pharmacogenomics. translating functional genomics into rational therapeutics Science. 286:1999;487-491.
8. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry. 267:1992;83-90.
9. Hadidi H., Zahlsen K., Idle J.R., Cholerton S. A single amino acid substitution, Leu160His, in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food and Chemical Toxicology. 35:1997;903-907.
10. Hanioka N., Gonzalez F.J., Lindberg N.A., Gelboin H.V., Korzekwa K.R. Site-directed mutagenesis of cytochrome P450s CYP2A1 and CYP2A2. influence of the distal helix on the kinetics of testosterone hydroxylation Biochemistry. 31:1992;3364-3370.
11. Hecht S.S., Hochalter J.B., Villalta P.W., Murphy S.E. 2′-Hydroxylation of nicotine by cytochrome P4502A6 and human liver microsomes. formation of a lung carcinogen precursor Proceedings of the National Academy of Sciences of the USA. 97:2000;12493-12497.
12. Honkakoski P., Negishi M. The structure, function and regulation of cytochrome P4502A enzymes. Drug Metabolism Reviews. 29:1997;977-996.
13. Ingelman-Sundberg M., Oscarson M., McLellan R.A. Polymorphic human cytochrome P450 enzymes. an opportunity for individualized drug treatment Trends in Pharmaceutical Science. 20:1999;342-349.
14. Jones B.C., Tyman C.A., Smith D.A. Identification of the cytochrome P450 isoforms involved in O-demethylation of 4-nitroanisole in human liver microsomes. Xenobiotica. 27:1997;1025-1037.
15. coh by mutation of glycine-207 to proline. spin equilibrium, enzyme kinetics and heat sensitivity Biochemical Journal. 294:1993;31-34.
16. Kimonen T., Pasanen M., Gynther J., Poso A., Jarvinen T., Alhava E., Juvonen R.O. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP2A5 and human CYP2A6. British Journal of Pharmacology. 116:1995;2625-2630.
17. Lewis D.F.V. Cytochromes P450: Structure, Function and Mechanism. 1996;Taylor & Francis, London.
18. Lewis D.F.V. The CYP2 family. models, mutants and interactions Xenobiotica. 28:1998;617-661.
19. Lewis D.F.V. Guide to Cytochromes P450. 2001;Taylor & Francis, London.
20. Lewis D.F.V. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica. 32:2002;305-323.
21. Lewis D.F.V., Dickins M. Quantitative structure-activity relationships (QSARs) within series of inhibitors for mammalian cytochromes P450 (CYPs). Journal of Enzyme Inhibition. 16:2001;321-330.
22. Lewis D.F.V., Dickins M., Lake B.G., Eddershaw P.J., Tarbit M.H., Goldfarb P.S. Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Toxicology. 133:1999;1-33.
23. Lewis D.F.V., Gorrod J.W. Molecular orbital calculations and nicotine metabolism. a rationale for experimentally observed metabolite ratios Drug Metabolism and Drug Interactions. 29:2002;29-39.
24. Lewis D.F.V., Lake B.G. Molecular modelling of member of the P4502A subfamily. application to studies of enzyme specificity Xenobiotica. 25:1995;585-598.
25. Lewis D.F.V., Lake B.G. Species differences in coumarin metabolism. a molecular modelling evaluation of CYP2A interactions Xenobiotica. 32:2002;547-561.
26. Lewis D.F.V., Modi S., Dickins M. Quantative structure-activity relationships within substrates of human cytochromes P450 involved in drug metabolism. Drug Metabolism and Drug Interactions. 18:2001;221-242.
27. coh substrate specificity by mutation of a single amino-acid residue. Nature. 339:1989;632-634.
28. Liu C., Zhuo X., Gonzalez F.J., Ding X. Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2A6. role in metabolic activation of nasal toxicants Molecular Pharmacology. 50:1996;781-788.
29. Messina E.S., Tyndale R.F., Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics. 282:1997;1608-1614.
30. Nakajima M., Yamamoto T., Nunoya K.-I., Yokoi T., Nagashima K., Inove K., Funae Y., Shimada N., Kamataki T., Kuroiwa Y. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics. 277:1996;1010-1015.
31. Negishi M., Iwasaki M., Juvonen R.O., Sueyoshi T., Darden T.A., Pedersen L.G. Structural flexibility and functional versatility of cytochrome P450 and rapid evolution. Mutation Research. 350:1996;43-50.
32. Negishi M., Uno T., Darden T.A., Sueyoshi T., Pedersen L.G. Structural flexibility and functional versatility of mammalian P450 enzymes. FASEB Journal. 10:1996;683-689.
33. Nunoya K.-I., Yokoi T., Kimura K., Kodama T., Funayama M., Inoue K., Nagashima K., Funae Y., Shimada N., Green C., Kamataki T. (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P4502A6 in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics. 277:1996;768-774.
34. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene. implications for interindividual differences in nicotine metabolism Drug Metabolism and Disposition. 29:2001;91-95.
35. 1 with cytochrome P450 2A5 and its mutants. correlation with metabolic activation and toxicity Chemical Research in Toxicology. 10:1997;85-90.
36. Pelkonen O., Rautio A., Raunio H., Pasanen M. CYP2A6. a human coumarin 7-hydroxylase Toxicology. 144:2000;139-147.
37. Poso A., Gynther J., Juvonen R. A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors. Journal of Computer-Aided Molecular Design. 15:2001;195-202.
38. Reigh G., McMahon H., Ishizaki M., Ohara T., Shimane K., Esumi Y., Green C., Tyson C., Ninomiya S.-I. Cytochrome P450 species involved in the metabolism of quinoline. Carcinogenesis. 17:1996;1989-1996.
39. Rendic S., DiCarlo F.J. Human cytochrome P450 enzymes. a status report summarizing their reactions, substrates, inducers and inhibitors Drug Metabolism Reviews. 29:1997;413-580.
40. Shimada T., Yamazaki H., Guengerich F.P. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica. 26:1996;395-403.
41. m isoforms Drug Metabolism and Disposition. 26:1998;605-607.
42. Spracklin D.K., Thummel K.E., Kharasch E.D. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P4502A6 and 3A4. Drug Metabolism and Disposition. 24:1996;976-983.
43. Su T., Bao Z., Zhang Q.-Y., Smith T.J., Hong J.-Y., Ding X. Human cytochrome P450 CYP2A13. predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specifc carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone Cancer Research. 60:2000;5074-5079.
44. Taavitsainen P., Juvonen R., Pelkonen O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropane (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metabolism and Disposition. 29:2001;217-222.
45. Torchin C.D., McNeilly P.J., Kapetanovic I.M., Strong J.M., Kupferberg H.J. Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes. Drug Metabolism and Disposition. 24:1996;1002-1008.
46. Walter, B.A., Hundal, J.S., 1994. In vitro metabolism of fadrozole (CGS16939A) in human microsomes and human cell lines expressing a single P450 isozyme. Proceedings of the 6th North American ISSX Meeting, Rayleigh, NC, 23-27 October, Vol. 6, p. 187.
47. Williams P.A., Cosme J., Sridhar V., Johnson E.F., McRee D.E. Mammalian cytochrome P450 monooxygenase. structural adaptations for membrane binding and functional diversity Molecular Cells. 5:2000;121-131.
48. Xu C., Rao Y.S., Xu B., Hoffmann E., Jones J., Sellers E.M., Tyndale R.F. An in vivo, pilot study characterizing the new CYP2A6*7, *8 and *10 alleles. Biochemical and Biophysical Research Communications. 290:2002;318-324.
49. Yamano S., Tatsuno J., Gonzalez F.J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 29:1990;1322-1329.
50. Yokoi T., Kamataki T. Genetic polymorphism of drug metabolizing enzymes. new mutations on CYP2D6 and CYP2A6 genes in Japanese Pharmaceutical Research. 15:1998;517-524.
51. Zhang W., Kilicarslan T., Tyndale R.F., Sellers E.M. Evaluation of methoxsalen, tranylcypromine and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metabolism and Disposition. 29:2001;897-902.